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Studies on the effects of caffeine on health, while numerous, have produced inconsistent results. One of the most uncertain and controversial
effects is on pregnancy outcome. Studies have produced conflicting results due to a number of methodological variations. The major challenge
is the accurate assessment of caffeine intake. The aim of the present study was to explore different methods of assessing caffeine exposure in
pregnant women. Twenty-four healthy pregnant women from the UK city of Leeds completed both a detailed questionnaire, the caffeine assess-
ment tool (CAT) designed specifically to assess caffeine intake and a prospective 3 d food and drink diary. The women also provided nine saliva
samples over two consecutive days for estimation of caffeine and a metabolite (paraxanthine). Caffeine intakes from the CAT and diary showed
adequate agreement (intra-class correlation coefficient of 0·5). For saliva caffeine and paraxanthine measures, the between-sample variation (within
the same woman) was greater than between-woman and between-day variation. However, there was still adequate agreement between these
measures and the CAT. The CAT is a valuable tool that is now being used in a large prospective study investigating caffeine’s role in pregnancy
outcome.
Caffeine: Assessment: Pregnancy
Caffeine or 1,3,7-trimethylxanthine exhibits a wide range of
physiological effects(1), in particular, it is a stimulator of the cen-
tral nervous system. It is rapidly absorbed from the gastrointes-
tinal tract and crosses the placenta. Caffeine originates in the
cocoa bean, tea leaf, mate leaf, kola nut, cocoa pod and guarana
seeds, and is naturally found in coffee, tea, cola, cocoa, dietary
supplements and herbal products. Smaller amounts are present
in products derived from cocoa and chocolate- or coffee-fla-
voured desserts and it is also added to soft drinks, ‘energy’
drinks, and prescription and non-prescription drugs.
A particular interest with respect to caffeine is the possible
effect on development in utero. An early study in mice
showed increased congenital malformations in the offspring of
micewhen treatedwith caffeine(2).More recent epidemiological
studies have led to the conclusion that caffeine intakes during
pregnancy .300mg/d carry an increased risk of both spon-
taneous miscarriage and low birth weight(3). However, the epi-
demiological studies have been contradictory, in part due to
different approaches to measuring caffeine intake. A number
of studies have found a relationship between relatively high caf-
feine consumption and low birth weight(4–6), whereas others
suggest that caffeine does not have an adverse effect on birth
weight(7–10).
Differences between studies may have occurred for a number
of reasons. Some did not consider changes in intake during
pregnancy. Timing of caffeine assessment is important since
many pregnant women reduce, or discontinue, caffeine intake
during pregnancy, either consciously, or due to nausea or a
heightened sense of smell. Other studies only measured
caffeine intakes after pregnancy(6,9). In addition, many investi-
gations often used a limited approach to assess caffeine intake.
Studies have used coffee consumption as a proxy for caffeine
intake, or simply counting the number of drinks and averaging
caffeine content according to beverage(11–13). To date, no study
of caffeine and pregnancy has made a comprehensive analysis
of all food, drinks and drugs containing caffeine, nor has any
study considered in detail the variation in caffeine content of
individual portion sizes and brands of these foods and drinks.
Misclassification of caffeine consumption makes it more diffi-
cult to identify health effects from caffeine and reduces com-
parability among studies.
Even if the caffeine content of different items of food and
drink can be accurately identified, there remains the problem
of accurate recall of intake. Biomarkers, such as caffeine
and its metabolites in body fluids, may offer an adjunct to
questionnaire-based assessments of intake. However, there
are substantial inter-individual variations in caffeine metab-
olism which would be expected to influence the correlation
between measured caffeine intake and plasma concentrations.
In addition, during pregnancy the half-life of caffeine is
increased. Despite this caveat, plasma concentrations of
the caffeine metabolite paraxanthine and, to a lesser extent,
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caffeine itself did distinguish between different levels of caf-
feine intake in women during pregnancy(14). Paraxanthine
has both a longer half-life in blood than caffeine and concen-
trations vary throughout the day. Plasma paraxanthine is less
sensitive to recent intake of caffeine and may therefore be a
better marker of caffeine consumption than plasma caffeine.
A less invasive approach, important during pregnancy or for
studying children, may be to measure caffeine in saliva.
Saliva drug concentrations are frequently related to unbound
drug concentrations in plasma(15,16) and caffeine intake has
been correlated to both saliva caffeine and paraxanthine(17).
The present study will inform a larger one investigating the
role of caffeine in pregnancy outcome, in particular, low birth
weight. The main study uses the caffeine assessment tool
(CAT) at three time points to explore caffeine intake through-
out pregnancy. The aim of the project reported here was to
explore three different methods of assessing caffeine exposure
in pregnant women during the first trimester only, using a
CAT, a 3 d food and drink diary, and salivary concentrations
of caffeine and paraxanthine.
Materials and methods
Subjects and samples
All pregnant women aged 18 years old or over, attending the
antenatal clinic at Leeds General Infirmary (Leeds, UK) were
eligible. Pregnant women younger than 18 years of age or who
were receiving their maternity care elsewhere were not eli-
gible to take part. Maternity records of women attending
the clinic were checked for suitable women. Women were
approached by the research assistant, informed about the
study, and given an information sheet. Women who agreed
to take part were given a background questionnaire, CAT,
3 d food and drink diary, and nine Salivettesw (Sarstedt
Aktiengesellschaft and Co., Nu¨mbrecht, Germany) to take
home, complete and return. The study protocol was approved
by the local research ethics committee and written informed
consent was obtained from all subjects.
Using the CAT, the present study assessed caffeine intakes
from weeks 5 to 12 of pregnancy only since this was the most
appropriate time frame relative to the stage of pregnancy when
most women attend the antenatal clinic for the first time, when
women are called to the clinic at about 16 weeks of preg-
nancy. The food and drink diary was completed at the same
time as the CAT although the time frames did not overlap.
The diary asked about 3 d of intake at the time of completion
whereas the CAT requested recall of intake during weeks 5–
12 of pregnancy. While completing the food and drink diary,
the women collected a total of nine saliva samples over two
consecutive days. Women noted both the time of consumption
of foods and drinks and of the saliva collection in the diary to
ensure that the saliva measurements provided biomarkers of
actual consumption for comparison with the recorded dose
(food and drink diary). The saliva samples were also used to
assess variation in salivary caffeine and paraxanthine concen-
trations at different times during the day, and between
days. Each saliva sample was collected in a Salivettew (Sar-
stedt Aktiengesellschaft and Co.). The Salivettew consists of
an outer centrifuge vessel containing a suspended insert
and cotton wool swab. Women were required to keep the
Salivettew swab in their mouth for 10min to ensure adequate
saliva collection. A sample interval of 90min was chosen
between collections to cause minimal disruption to normal
daily activity. On the first day, each woman provided saliva
samples every 90min over a 9 h period, involving a total of
seven saliva samples. To avoid the presence of caffeine in
the saliva due to recent consumption (rather than following
absorption), the women were asked to avoid caffeine-contain-
ing foods and drinks, listed on a sheet provided, for 1 h before
collecting the first sample, and for 15min before taking each
of the following six samples. The women were also asked to
rinse their mouth with tap water before collection. On the
second day, the same women were asked to provide a further
two saliva samples at approximately mid-morning and mid-
afternoon to reflect likely time of sample collection in the
larger study. Again the women were asked to avoid caf-
feine-containing foods and drinks for 1 h before sample collec-
tion and to rinse their mouth with tap water before the samples
were taken. The women were told to refrigerate the samples
until they were returned by post to the research team along
with the background questionnaire, CAT and diary.
Analysis of caffeine intakes
The CAT was developed to assess caffeine intakes from all
possible sources of caffeine in a FFQ style, taking into account
specific brand, preparation and portion size information. Since
the CAT was developed to assess caffeine intake during preg-
nancy, questions on consumption of caffeine-containing foods
and beverages were repeated to assess intakes during different
weeks of pregnancy. Brand information was collected on
coffee, tea, hot chocolate, cola and energy drinks, and was
categorised into types of drink, for example, instant, filter,
iced, and place of consumption to remind women of beverage
consumption outside the home or workplace. Further questions
requested portion sizes of tea, coffee and cola, changes in
intake of tea and coffee during pregnancy, methods of prep-
aration, and intakes of foods which may affect caffeine metab-
olism, for example, cruciferous vegetables, grapefruit and
barbecued foods(18–20). The caffeine content of foods and bev-
erages were obtained from a UK government report by the
Ministry of Agriculture, Fisheries and Food(21) and also
from manufacturers and coffee-houses, providing caffeine
values for twenty-nine instant coffees, nine filter coffees,
three coffee-house filter coffees, a standard espresso shot
and decaffeinated shot, eight instant beverage mixtures,
seven espresso-based drinks, eighteen hot chocolates,
twenty-five teas prepared from tea bags, seventeen teas pre-
pared from tea leaves, one iced-tea, three instant teas, thirty-
six colas, thirty-three energy drinks, eleven soft drinks and
two alcoholic drinks. Each of the above beverages had a stan-
dard caffeinated and decaffeinated value assigned based on the
average caffeinated and decaffeinated content of each drink.
For each of the chocolate items a value was assigned based
on the average caffeine content from various brands. The caf-
feine content of fifty-nine over-the-counter drugs was accessed
from manufacturers’ websites. The CAT also assesses possible
confounders, for example, smoking habits, alcohol intake, use
of medication and symptoms of pregnancy. The CAT is
thus the most detailed and comprehensive tool to assess caf-
feine intake during pregnancy which is currently available.
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A detailed computer algorithm was developed which assigned
a value for caffeine content (mg) to all caffeinated products
assessed in the CAT while taking into account portion sizes,
brand information and frequency of intakes. Daily caffeine
intake during weeks 5–12 of pregnancy could be calculated
for each participant.
The food and drink diaries were analysed manually for each
woman’s daily caffeine intake. All caffeine-containing foods
and drinks recorded in the diaries were allocated a caffeine
value depending on amount and type of food or drink con-
sumed. A mean caffeine value was calculated for each food
and beverage source and assigned to any unbranded sources
recorded in the diaries.
Analysis of saliva
Caffeine and metabolites were extracted and quantified using
liquid:liquid extraction and reversed-phase HPLC with UV
detection using a modification of the method of Butler
et al. (22). Salivettesw were thawed and saliva reclaimed by
centrifugation at 756 g for 5min at room temperature.
Saliva (180ml) was added to a 5ml screw-cap tube containing
50mg ammonium sulfate following which 20ml of a stock
solution of b-hydroxyethyltheophylline (20 ug/ml) was
added as internal standard. The tube was shaken vigorously
for 10 s using a Baxter multi tube vortex (Alpha Laboratories,
Eastleigh, Hants, UK) on setting 4, to thoroughly mix the
contents and precipitate any protein. This was followed by
the addition of chloroform (2·0ml) and isopropanol (0·5ml)
and the tube shaken again for 4min on setting 4. After cen-
trifuging for 5min (84 g) the aqueous top layer was discarded
and the organic layer transferred to a thick-walled glass tube
and dried down under N2 at 458C. The residue was reconsti-
tuted in 30% methanol in water (200ml), mixed vigorously
for 3 s and centrifuged for 2min (756 g) to give a final con-
centration of b-hydroxyethyltheophylline of 2mg/ml. The
reconstituted solution was transferred to an autosampler vial
and 30ml injected onto a Beckman Ultrasphere column
(ODS; 4·6mm £ 25 cm) with a short guard column
(5 cm £ 0·4 cm) packed in-house with Bondapak C18/corasil
(Waters, Elstree, Herts, UK). The solvent delivery system,
autosampler and UV detector were manufactured by Gilson
(Paris, France). UV wavelength was set at 280 nm. Solvents
used for elution were 0·045% acetic acid containing 9%
methanol (A) and 100% methanol (B). Starting with solvent
A, elution was a linear gradient over 5min to a 2% solution
of solvent B, held at this for 10min, over the next 5min
increased in a linear gradient to 5% solvent B, followed by
a linear increase over 5min to 8% B, changed to 15% B
and maintained for 15min, raised to 75% B and held at
this for 10min, followed by reversion to 100% A (the starting
solvent) which was maintained for 10min to equilibrate the
column before injection of the next sample. The flow rate
was 1·2ml/min and the retention time, in min, for each com-
pound was approximately: theobromine, 10·3; 1,7-dimethylu-
ric acid, 14·8; paraxanthine, 16·2; theophylline, 17·7; b-
hydroxyethyltheophylline, 22·4; caffeine (1,3,7-trimethyl-
xanthine), 29·5. Retention times varied slightly from day to
day and were adjusted accordingly to produce optimum
identification of each analyte when processing results. A
single standard containing all the above compounds at the
same concentration (5mg/ml) was made up in 30% methanol;
this was run after every five samples. Two ‘in-house’ quality-
control samples were also extracted and run with each batch
of eighteen samples. Quality-control samples were made by
spiking ‘blanked saliva’ with 5mg/ml of each compound.
The saliva, donated by volunteers, was collected in Salivet-
tesw and ‘blanked’ by gentle mixing with charcoal (0·1 g/
ml) for 24 h, centrifuged (728 g) for 10min and the super-
natant fraction filtered through a 0·20mm filter and stored at
2208C until spiked. When in use, quality-control material
was stored at 48C. Within-batch CV (%) were: theobromine,
2·3; 1,7-dimethyluric acid, 2·4; paraxanthine, 2·2; theophyl-
line, 2·5; b-hydroxyethyltheophylline, 3·1; 1,3,7-trimethyl-
xanthine, 2·7. Between-batch CV (%) were: theobromine,
2·8; 1,7-dimethyluric acid, 2·5; paraxanthine, 2·2; theophyl-
line, 3·0; b-hydroxyethyltheophylline, 2·4; 1,3,7-trimethyl-
xanthine, 3·8. The limit of quantification was 50 ng/ml for
all compounds, calculated from standards made up in 30%
methanol with no extraction. The assay was linear between
50–10 000 ng/ml for all the above compounds.
Caffeine, other methylxanthine metabolites and ammonium
sulfate were purchased from Sigma (Poole, Dorset, UK) and
all extraction and eluant reagents were supplied by Rathburn
Chemicals (Walkerburn, Peebleshire, UK).
Statistical analysis
Statistical analysis was carried out using SPSS (version 10.1;
SPSS Inc., Chicago, IL, USA), Stata (version 8.2; StataCorp
LP, College Station, TX, USA) and MlwiN (University of
Bristol, Bristol, UK)(23). Caffeine intakes from the CAT and
3 d diary were compared. k Statistics were carried out to test
the agreement between the caffeine intakes estimated either
by the CAT or the diary (split at the median), and the mean
of the seven saliva caffeine and paraxanthine measures on
day 1, and the mean of the two saliva caffeine and para-
xanthine measures on day 2. The total 3 d diary and the indi-
vidual diary days which related to the day of saliva sample
collection were used for this analysis. Time of gestation
(weeks) was categorised into two groups (see Table 1 for cat-
egorisation), and agreement between the CAT and 3 d diary
was estimated within each group as well as for the group as
a whole. A variance components model was used to investi-
gate the variance structure of the data and estimate the intra-
class correlation coefficient (ICC) of agreement taking all
sources of error into account.
Results
Characteristics of women
A total of sixty-three women were recruited, but only twenty-
four completed the study. The mean age of the women was
31·7 (SD 3·4) years, with the mean gestation being 16·3 (SD
6·9) weeks. According to the Office for National Statistics
socio-economic classification (SEC) self-coded method(24) of
calculating SEC status, the number of women classed as work-
ing in managerial and professional occupations, intermediate
occupations, and as a small employer with account workers,
were sixteen, five and one respectively. Two women did not
fully complete the question on SEC status.
Caffeine exposure in pregnant women 877
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
Caffeine intakes
The highest mean daily caffeine intakes calculated from the
CAT and diary were among women who were of later ges-
tation (Table 1). On average, the daily caffeine intake from
the CAT at 128 (SD 129) mg/d was 15mg more than the
diary at 113 (SD 97) mg/d. This difference is small, being
approximately one-fifth of a cup of instant coffee. The caf-
feine intakes from the CAT and the diary among the total
sample (n 24) showed adequate agreement (ICC ¼ 0·5). Ten
of the women did not provide complete brand information
on sources of caffeine intake in the diary despite doing so in
the CAT. For these women, the mean daily caffeine intake
from the CAT was 156 (SD 77) mg/d which was 27mg/d
more than the diary at 129 (SD 80) mg/d. However, for the
women who did provide complete brand information in the
diary, the mean daily caffeine intake from the CAT was 108
(SD 156) mg/d; this was only 6mg/d more than caffeine
intake assessed from the diary at 102 (SD 109) mg/d. It is
also evident that these women had lower caffeine intakes
from both the CAT and diary than those who did not provide
complete brand information in the diaries. Figure 1 illustrates
the agreement between mean caffeine intake (mg/d) from the
CAT and diary. The level of agreement between the two
methods was greater for women who were #15 weeks ges-
tation (ICC ¼ 0·69) compared with those between 16 and 37
weeks gestation (ICC ¼ 0·29) (Table 1). A greater level of
agreement was also apparent when women who left education
earliest were considered (ICC ¼ 0·69) compared with those
who left education later (ICC ¼ 0·20). Level of agreement
between the two methods was similar for both young and
old women (ICC ¼ 0·50 and 0·46, respectively).
Variability of saliva measures
All nine saliva samples were available from sixteen women.
The mean saliva caffeine and paraxanthine concentrations
were 454 (95% CI 367, 561) and 198 (95% CI 165, 237)
ng/ml respectively. There was good agreement between days
1 and 2 of saliva collection for both saliva caffeine and para-
xanthine (ICC ¼ 0·66 and 0·65, respectively). Figure 2 illus-
trates the saliva sample concentrations and caffeine intake
over the first day of saliva collection. It is evident from
Fig. 2 that saliva caffeine and paraxanthine concentrations
reflected each other closely for most women, for example,
Fig. 2(a, b, f, j, k, u); however, this was not the case for a
few of the women, for example, Fig. 2(i, p). It is also evident
from Fig. 2 that salivary caffeine and paraxanthine concen-
trations reflected caffeine intake for some of the women, for
example, Fig. 2(a, g, h, m). For some women, irrespective
of level of caffeine intake, there was a sudden increase in
saliva concentrations after caffeine intake, for example,
Fig. 2(a, g, v). For others, however, saliva concentrations
did not parallel caffeine intake, for example, Fig. 2(b, o), or
had a delay in the development of peaks, for example,
Fig. 2(h). Caffeine intakes were low for some women; there-
fore, peaks in saliva caffeine and paraxanthine concentrations
were not as marked, for example, Fig. 2(i, r).
For both saliva caffeine and paraxanthine, the between-
sample (i.e. within the same woman) variation was 50 and
61% of total variation, respectively, for example, Fig. 2(k)
which shows considerable variation in saliva caffeine and
paraxanthine between samples. Between-women variation
for salivary caffeine and paraxanthine was 39 and 38% of
total variation, respectively. Figure 2(b, k) shows how variable
these concentrations are between women. Between-day vari-
ation for saliva caffeine and paraxanthine was relatively low
at 11 and 0·1% of total variation, respectively. Despite this
variation, however, the CAT agreed with the saliva measures
just as well as with the food and drink diary. Using the k stat-
istic, there was a moderate agreement between the CAT and
saliva caffeine collected on both days 1 and 2 (0·50 and
0·47, respectively), with an even better agreement between
the CAT and saliva paraxanthine collected on day 2 (0·65).
Using the mean caffeine intake calculated over 3 d from the
diary, a moderate agreement existed between the diary and
Table 1. Caffeine intake (mg/d) and time of caffeine assessment tool (CAT) completion
(Mean values and standard deviations)
Time of CAT and diary completion
Total group (n 24) #15 weeks gestation (n 13) .15 weeks gestation (n 11)
Tool Mean SD k* Mean SD k* Mean SD k*
CAT 128·2 129·2 0·50 123·4 90·7 0·69 133·8 168·7 0·29
Diary (mean intake over 3 d) 113·2 97·0 98·4 91·2 130·1 105·0
*kStatistic comparing CAT and diary.
Fig. 1. Bland–Altman scatter plot of difference in caffeine intakes (mg/d)
between the caffeine assessment tool (CAT) and food and drink diary.
S. M. Boylan et al.878
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Fig. 2. Saliva measures of caffeine (ng/ml; —) and paraxanthine (ng/ml; - - -) collected on day 1 and caffeine intake (mg; W) on the same day for each woman (a to x).
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saliva paraxanthine collected on both day 1 and 2 (0·50 and
0·47, respectively), with a greater agreement between
the diary and saliva caffeine collected on day 1 (0·66).
As expected, this agreement was even better when saliva con-
centrations were compared with caffeine intake from the diary
on the same day of sample collection (Table 2).
Discussion
Caffeine intakes
The mean caffeine intakes from both the CAT and diary were
lower than intakes previously reported by pregnant women in
the UK (204mg/d for a 60 kg woman)(25). However, since this
previous study, a report has been published by the Food Stan-
dards Agency (FSA) advising pregnant women to limit caf-
feine consumption to less than 300mg/d(3), and this may
have decreased pregnant women’s caffeine intakes in the
UK. It is also possible that some women may have decreased
or under-reported their caffeine intake as a result of taking part
in the present study.
The CAT is a detailed assessment of caffeine intake which
is straightforward to complete. In contrast, ten women did not
provide detailed information on caffeine intake particularly
relating to brand-level information in the diary even though
they were instructed to do so. This may have contributed to
the overall difference in estimated caffeine intakes between
the CAT and the diary. There was a greater difference between
caffeine intakes from the CAT and diaries from women who
did not provide complete brand information compared with
women who did provide this level of information in the dia-
ries. Another contributor to difference in estimates of caffeine
intakes between the two methods could be the different time
periods assessed by the two tools. The diary assessed food
and drink consumption over the 3 d whereas the CAT assessed
recalled intakes over an 8-week period. Despite the difference
in estimates, there was still an adequate agreement between
the two methods.
The level of agreement between the caffeine intakes from
the CAT and diary was greatest among women who were in
their earliest gestational weeks. This may be because the
CAT that was administered in this test assessed caffeine
intake early in pregnancy (weeks 5–12). Women later in
pregnancy reported higher caffeine intakes in the CAT
(Table 1), although only four women were in the second
half of pregnancy (over 20 weeks); nevertheless, recall bias
may have been introduced as these women may have been
reporting caffeine intakes similar to their current intakes
rather than intakes between weeks 5 and 12 of pregnancy.
This is plausible, as caffeine intake may be lower in the first
trimester due to nausea or intentional avoidance.
Saliva samples
In general, salivary caffeine and paraxanthine concentrations
agreed with and reflected each other closely. It is also clear
that the saliva concentrations generally responded to the caf-
feine intake recorded. However, for some of the women, the
saliva measures did not appear to increase after reported caf-
feine intake. This may be due to error in completing the
diary, or due to differences in metabolism and clearance
between women resulting in lower concentrations at the time
samples were collected. Caffeine is metabolised by the cyto-
chrome P450 family of enzymes in the liver, in particular the
major enzyme being cytochrome P450 1A2 (CYP1A2)(26)
with metabolites produced through demethylation and oxi-
dation. Paraxanthine is a primary metabolite produced by
demethylation of the N 3 position methyl group. Caffeine has
a half-life of about 3–7 h unless the rate of action is affected
by genetic and/or environmental factors, for example,
CYP1A2 activity is decreased by female sex hormones during
pregnancy or treatment with oral contraceptives(27).There is
wide variation in CYP1A2mRNA expression; up to 40-fold
variation has been described(28,29). Genetic polymorphisms of
the CYP1A2 gene, smoking, chargrilled foods, brassica veg-
etables and prescription medicines also affect the rate of caf-
feine metabolism(30). Saliva measures were chosen in
preference to blood and urine due in part to the ease of obtaining
the samples and the lower invasiveness of the measure for the
subjects. Plasma and saliva clearance levels of caffeine are
highly correlated(31). Newton et al. (32) concluded that salivary
caffeine levels probably reflect the unbound plasma caffeine
concentration and therefore can be used to estimate the pharma-
cokinetic parameters of the drug. They estimated that the over-
all saliva:plasma concentration ratio was 0·74 (SD 0·08). Other
evidence has suggested that the complex metabolism of caf-
feine, together with different parameters controlling the renal
clearance of each metabolite, makes the use of urinary meta-
bolic ratios an inaccurate probe in populations(33).
For the saliva measures, the between-sample variation was
greater than the between-woman and between-day variation.
This is expected, as the serum and saliva concentration of
caffeine varies widely in response to recent caffeine intake.
However, because of its longer half-life, paraxanthine concen-
trations will fluctuate less throughout the day and may be a
better measure of caffeine intake. However, in the present
study, the between-sample variation of saliva caffeine was
lower than the between-sample variation of saliva paraxanthine.
Despite this relatively large variability, Table 2 shows that, in
general, both saliva measures adequately agreed with both the
CAT and diary. As expected, the greatest level of agreement
between the saliva measures and assessment of caffeine intake
was found between seven saliva samples collected on day 1
and actual caffeine intake on that day, illustrating that a 1 d
diary is a good snapshot of actual caffeine intake. Several
measurements of salivary caffeine and paraxanthine over a
day are far more likely to reflect intake than a single measure-
ment. Both caffeine and paraxanthine have relatively short
Table 2. Agreement between caffeine intakes and saliva caffeine and
paraxanthine measures
Day of sample
collection
Coefficient of
agreement (k)
Tool Caffeine Paraxanthine
Caffeine assessment
tool
1 0·50 0·33
2 0·47 0·65
Diary (intake on day
of saliva collection)
1 0·74 0·57
2 0·45 0·64
Total of 3 d of diary 1 0·67 0·50
2 0·30 0·48
S. M. Boylan et al.880
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half-lives and concentrations in saliva (or plasma) changemark-
edly over a day, reflecting recent consumption. Given that caf-
feine intake over the day is episodic, repeat measurements of
salivary caffeine and paraxanthine are more likely to record
this pattern of consumption than a single measurement at one
time point.
A moderate, yet lower, agreement was found between the
saliva measures and the more habitual intake calculated
from the mean caffeine intake of the 3 d reported in the
diary. Even though the CAT reflects longer-term habitual caf-
feine intake than the 3 d diary, the agreement between the
CAT and saliva measures was only marginally less than that
between the 3 d diary and saliva measures.
General comments
Despite using different methodologies, both the CAT and
diary have emerged as equally good in assessing caffeine
intake. However, it is the CAT that provides a practical, yet
detailed, and therefore more accurate assessment of long-
term habitual caffeine intake.
Only 38% of the women recruited took part in the present
study, which could be due to the demands of completing a 3 d
food and drink diary and collecting nine saliva samples and
monitoring caffeine intake over 2 d. It is important to consider
that this sample of women may not be representative of the
total pregnant population, as approximately one-third of the
sample were employed in managerial and professional
occupations.
As is evident from the present study, assessing long-term
caffeine intake using food and drink diaries is not only
impractical, but it is also likely to omit detail such as
brand information. In the present study it was apparent that
when such information was omitted from diaries, estimated
caffeine intakes were on average 27mg/d lower than intakes
from the more detailed CAT – which is approximately
equivalent to half a cup of tea. This suggests that the use
of average values for sources of caffeine intake may under-
estimate caffeine intakes. A further source of error could
be introduced by not considering strength of tea or coffee
as commonly consumed. Different preparatory approaches
to making tea or coffee can lead to variations in caffeine con-
tent(34). We did ask women to record (in the CAT) the
strength of tea and coffee they prepared and to state whether
it was weak, medium or strong. We did not use this infor-
mation, however, since there was limited published infor-
mation available on variation in caffeine content by brand
and preparation method. For instant coffee we did record
and use in our analysis whether level or heaped teaspoons
of dry coffee were used. Our previous experience of asses-
sing diet has indicated that individual perceptions will vary
and thus we could introduce more measurement error by
using more subjective records. In addition, brewing times
for cafetie`re-prepared coffee makes little difference to caf-
feine content of the brewed drink (PK Kadja, personal com-
munication).
Repeated saliva measures may also be a useful measure of
caffeine exposure. However, even if caffeine intake was accu-
rately assessed, there exist inter-individual differences in
metabolism that will influence spot saliva measurements.
This may be especially relevant when assessing effects of
caffeine exposure on pregnancy outcome, as caffeine metab-
olism decreases throughout pregnancy(35).
A study is now being undertaken to assess the role of caf-
feine on pregnancy outcome, in particular low birth weight.
Using the CAT, saliva measures of caffeine and metabolites,
and a more detailed exploration of the inter-individual vari-
ations in caffeine metabolism, it will be possible to elucidate
any links between caffeine and pregnancy outcome.
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